Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended. Dosage: The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability; amounts greater than 300 mL may be ...
Cystografin Dilute (Diatrizoate
Meglumine Injection USP 18%) is a radiopaque contrast agent supplied
as a sterile, aqueous solution. Each mL provides 180 mg diatrizoate
meglumine with 0.4 mg edetate disodium as a sequestering agent. Each
mL of solution also contains approximately 85 mg organically bound
iodine. At the time of manufacture, the air in the container is replaced
by nitrogen.
INDICATION
INDICATIONS & USAGE SECTION
Cystografin Dilute is indicated
for retrograde cystourethrography.
CONTRAINDICATIONS
CONTRAINDICATIONS SECTION
This preparation is contraindicated
in patients with a hypersensitivity to salts of diatrizoic acid.
WARNINGS
WARNINGS SECTION
Severe sensitivity reactions are
more likely to occur in patients with a personaI or family history
of bronchial asthma, significant allergies, or previous reactions
to contrast agents.
A
history of sensitivity to iodine per se or to other
contrast agents is not an absolute contraindication to the use of
diatrizoate meglumine, but calls for extreme caution in administration.
PRECAUTIONS
PRECAUTIONS SECTION
Safe and effective use of this
preparation depends upon proper dosage, correct technique, adequate
precautions, and readiness for emergencies.
Retrograde cystourethrography should be performed
with caution in patients with a known active infectious process of
the urinary tract.
Sterile
technique should be employed in administration. During administration,
care should be taken to avoid excessive pressure, rapid or acute distention
of the bladder, and trauma.
Contrast agents may interfere with some chemical determinations made
on urine specimens; therefore, urine should be collected before administration
of the contrast medium or two or more days afterwards.
Pregnancy–Teratogenic Effects:
TERATOGENIC EFFECTS SECTION
Animal reproduction studies have not been conducted
with diatrizoate meglumine injection. It is also not known whether
diatrizoate meglumine injection can cause fetal harm when administered
to a pregnant woman or can affect reproduction capacity. Cystografin
Dilute should be administered to a pregnant woman only if clearly
needed.
ADVERSE REACTIONS
ADVERSE REACTIONS SECTION
Retrograde genitourinary procedures
may cause such complications as hematuria, perforation of the urethra
or bladder, introduction of infection into the genitourinary tract,
and oliguria or anuria.
If intravasation of this drug occurs, the reactions which may be
associated with intravenous administration may possibly be encountered.
Hypersensitivity or anaphylactoid reactions may occur. Severe reactions
may be manifested by edema of the face and glottis, respiratory distress,
convulsions or shock; such reactions may prove fatal unless promptly
controlled by such emergency measures as maintenance of a clear airway
and immediate use of oxygen and resuscitative drugs.
Endocrine: Thyroid function
tests indicative of hypothyroidism or transient thyroid suppression
have been uncommonly reported following iodinated contrast media administration
to adult and pediatric patients, including infants. Some patients
were treated for hypothyroidism.
DOSAGE AND ADMINISTRATION
DOSAGE & ADMINISTRATION SECTION
SPL UNCLASSIFIED SECTION
Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative
the night before the examination and a low residue diet the day before
the procedure are recommended.
SPL UNCLASSIFIED SECTION
Dosage: The dose for
retrograde use in cystography and voiding cystourethrography ranges
from 25 to 300 mL depending on the age of the patient and the degree
of bladder irritability; amounts greater than 300 mL may be used if
the bladder capacity allows. Best results are obtained when the bladder
is filled with the contrast agent.
SPL UNCLASSIFIED SECTION
Administration: After
sterile catheterization, the bladder should be filled to capacity
with Cystografin Dilute using a suitable sterile administration set.
Care should be taken to avoid using excessive pressure. The presence
of bladder discomfort or reflux and/or spontaneous voiding usually
indicates that the bladder is full.
SPL UNCLASSIFIED SECTION
Radiography: The commonly
employed radiographic techniques should be used. A scout film is recommended
before the contrast agent is administered.
HOW SUPPLIED
HOW SUPPLIED SECTION
Cystografin Dilute (Diatrizoate
Meglumine Injection USP 18%) is available in packages of ten 300 mL
bottIes (NDC 0270-1410-30).
Storage
STORAGE AND HANDLING SECTION
Store at 20-25°C (68-77°F) [See
USP]; protect from light.
SPL UNCLASSIFIED SECTION
Revised June 2024
Rx only
Manufactured for Bracco Diagnostics Inc. Princeton, NJ 08540
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 11 · 440 observed states.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.